Transaction Overview
On March 19, 2025, Bleichroeder LP (Trades, Portfolio), an investment firm, made a significant addition to its holdings in Cue Biopharma Inc (CUE, Financial). The firm acquired 1,130,422 shares at a trade price of $0.9692 per share. This transaction resulted in a 0.27% increase in the firm's portfolio, bringing the total number of shares held to 6,127,662. Post-transaction, Cue Biopharma now constitutes 1.49% of Bleichroeder LP (Trades, Portfolio)'s portfolio.
About Bleichroeder LP (Trades, Portfolio)
Bleichroeder LP (Trades, Portfolio) is a prominent investment firm located at 1345 Avenue of the Americas, New York, NY 10105. While the firm's specific investment philosophy is not detailed, it manages a total equity of $398 million. The firm's top holdings include SPDR Gold Shares ETF (GLD, Financial), Linde PLC (LIN, Financial), S&P Global Inc (SPGI, Financial), Paragon 28 Inc (FNA, Financial), and CompoSecure Inc (CMPO, Financial). Bleichroeder LP (Trades, Portfolio) primarily invests in the Industrials and Healthcare sectors.
Company Profile: Cue Biopharma Inc
Cue Biopharma Inc, based in the USA, is a clinical-stage biopharmaceutical company that went public on January 2, 2018. The company focuses on developing biologics drugs aimed at modulating the human immune system to treat various cancers and autoimmune disorders. With a market capitalization of $62.010 million, Cue Biopharma's current stock price stands at $0.97885.
Financial and Valuation Metrics
Cue Biopharma's [Price-to-GF Value](https://www.gurufocus.com/term/gf-value/CUE) ratio is 0.39, indicating a possible value trap. The [GF Value](https://www.gurufocus.com/term/gf-value/CUE) is estimated at $2.51. The stock has experienced a year-to-date price change of -10.2% and a significant decline of -91.24% since its IPO. The company's [GF Score](https://www.gurufocus.com/term/gf-score/CUE) is 64/100, suggesting poor future performance potential.
Performance and Growth Indicators
Cue Biopharma's [Balance Sheet Rank](https://www.gurufocus.com/term/rank-balancesheet/CUE) is 4/10, while its [Profitability Rank](https://www.gurufocus.com/term/rank-profitability/CUE) is 2/10. The company shows a [Growth Rank](https://www.gurufocus.com/term/rank-growth/CUE) of 7/10, with a cash to debt ratio of 3.41. Over the past three years, revenue growth was 2.90%, [EBITDA growth](https://www.gurufocus.com/term/ebitda/CUE) was 13.80%, and earnings growth was 10.80%.
Market and Industry Context
Operating within the Biotechnology industry, Cue Biopharma has a return on equity (ROE) of -142.28 and a return on assets (ROA) of -82.16. The company's gross margin growth is 0.00, while its [Operating Margin](https://www.gurufocus.com/term/operating-margin/CUE) growth is 10.20. These metrics highlight the challenges faced by the company in achieving profitability.
Conclusion
Bleichroeder LP (Trades, Portfolio)'s strategic addition to Cue Biopharma Inc reflects a calculated move within the firm's portfolio. For value investors, this transaction may warrant a closer examination of Cue Biopharma's current valuation metrics and potential growth prospects. Despite the company's challenges, Bleichroeder LP (Trades, Portfolio)'s investment could signal confidence in Cue Biopharma's long-term potential within the biopharmaceutical sector.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
